Maternal and Congenital cytomegalovirus infection and zero rubella IgM prevalence in newborns in St.Paul’s Hospital Millennium Medical College by Yeshwondm Mamuye et al.




cytomegalovirus infection and zero rubella IgM 
prevalence in newborns in St.Paul’s Hospital 
Millennium Medical College
Yeshwondm Mamuye1*, Balkachew Nigatu2, Delayehu Bekele2 and Mekonen Getahun3
Abstract 
Background: Maternal cytomegalovirus (CMV) and Rubella infections result in adverse neonatal outcomes. Both 
CMV and Rubella are more widespread in developing countries and in communities with lower socioeconomic status. 
Thus, the aim of this study was to determine IgM specific to CMV and Rubella among newborns and Maternal CMV-
seroprevalence and to identify risk factors.
Method and finding: Using cross sectional study design a total of 312 (156 newborns and 156 mothers) study par-
ticipants were recruited by simple random sampling technique from gynecology outpatient department (OPD) and 
ward, starting from April 1, 2015 to June 30, 2015. Cord and venous blood samples were collected from all partici-
pants and structured questionnaire was introduced to gather risk factor related data. ELISA was used to detect CMV 
and Rubella-IgM. SPSS version 20 was used to analyze the data, and regression analysis was also performed. Out of 
156 newborns, 2 [1.3 %; 95 % CI: 0.0–3.8] were positive for CMV—IgM and no single rubella was detected. Association 
was not computed between risk related variables and cytomegalovirus infected newborns due to the low positiv-
ity rate. Multiple independent predictors were found between maternal CMV-IgM and Obstetrical characteristics. 
Cytomegalovirus—IgM was significantly isolated from mothers with history of transfusion (25.0 %, OR 0.09, 95 % CI 
0.0–0.3, P = 0.006), history of abortion (OR 0.02, 95 % CI 0.0–0.6, P = 0.023), HIV sero-status (OR 5.0, 95 % CI 1.5–15.8, 
P = 0.034), and multi parity (OR 0.08, 95 % CI 0.01–0.7, P = 0.022).
Conclusion: Although low congenital CMV and no Rubella are reported among newborns, more effort is needed 
to screen for congenital infectious viral disease as well as usage of advanced techniques should be taken into 
consideration.
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Background
Human cytomegalovirus (CMV) is a member of the fam-
ily Herpesviridae and belongs to the subfamily betaher-
pesviridae. CMV has worldwide distribution, infects 
humans of all ages and all socioeconomic groups, and 
with no seasonal or epidemic patterns of transmission 
[1]. It is the most common cause of con-genital infection 
with birth prevalence of about a range of 0.2–2.5 percent, 
and a common cause of deafness and intellectual impair-
ment worldwide [2–4].
In utero transmission of CMV can occur following pri-
mary maternal infection during pregnancy but can also 
occur in women with natural immunity, either because 
of the reactivation of latent virus or by re-infection with 
a different strain [5]. Postnatally, CMV is also transmit-
ted from mother to child through breastfeeding and 
close contact [6]. The transmission risk is the proportion 
of mothers undergoing a primary infection in a given 
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trimester and/or the preconception period who transmit-
ted CMV to the fetus [7].
Maternal infection especially during the first trimester 
associated with adverse neonatal outcome which encom-
pass heart disease, cataract and deafness collectively known 
as congenital rubella syndrome which had a major neonatal 
morbidity and burden to families [8]. Although, incidence of 
rubella infection is reduced worldwide, some African coun-
tries like Mozambique still have a high incidence (95.3 %) 
[9, 10]. Rubella vaccine is cost-effective and cost-beneficial, 
therefore since year 2000 WHO proposed an introduction 
of rubella vaccine program in each country [11].
Cytomegalovirus is one of the most common causes of 
congenital infections; however, in Ethiopia CMV infec-
tion rate among newborn is yet undetermined and this 
might worsen the outcome of the disease.
The aim of the study was to determine IgM specific to 
CMV and Rubella in newborns who delivered at Depart-
ment of Obstetrics and Gynecology of St. Paul’s Hospital 
Millennium Medical College. The recognition of congen-
ital CMV and Rubella among newborns in the country, 
helps to develop effective prevention and treatment pro-
tocols. Therefore, this study adds an important input on 
CMV burden data to design appropriate control meas-
ures for Ethiopian mothers and children. This study also, 
highlights improving awareness to clinicians and creating 
a public concern for the communities.
Methods
A cross sectional study was conducted at St. Paul’s Hos-
pital Millennium Medical College (SPHMMC), Addis 
Ababa, Ethiopia. It is located in an urban setting and 
serves as both a tertiary hospital for Ethiopia and teach-
ing hospital for national and international students. The 
hospital provides out and in patient services with a total 
of 372 beds. Accordingly, patients being seen at SPH-
MMC came from all over Ethiopia. The sample size for 
the study was calculated using the formula (n = (zα/2)2 p 
(1-p)/d2) for estimating a single population proportion at 
95 % confidence interval (CI) (Zα/2 = 1.96), 5 % margin 
of error, and 10  % non-respondents rate based on IgM 
specific prevalence of CMV from a study in Sub-Saha-
ran region among infants 3.8  % [12]. Then a total of 56 
sample size was calculated. However, by considering non 
respondent rate and design effect, the total number of 
newborn were increased to156. Therefore, 156 mothers 
were recruited using simple random sampling technique.
Data collection
Cord and venous blood samples were collected from 
selected study participants, who gave birth in gynecol-
ogy and obstetrics clinic, starting from April 1, 2015 to 
June 30, 2015. Serum from cord samples were collected 
under aseptic conditions, and transported using ice-
box to Ethiopian Public Health Institute (EPHI) and 
examined for the presence of CMV and Rubella spe-
cific IgM. Maternal serum samples were screened for 
CMV-IgG and CMV-IgM in St.Paul’s Hospital Millen-
nium Medical College clinical chemistry department.
Standard structured questionnaires were designed to 
collect information regarding socio-demographics char-
acteristics of the mother and risk related (weight, height, 
head circumference of the new born and maternal HIV 
sero-status, HBsAg, blood transfusion history,, history of 
abortion frequency of pregnancy and number of under 
five children) data. The questionnaire was first developed 
in English and translated into local language, Amharic. 
Questions were pre-tested in non-selected health insti-
tutions to assess the content validity, appropriateness, 
and question comprehensibility. The questionnaire was 
revised accordingly. Three data collectors from the insti-
tution in the study area were selected. Training was given 
to the data collectors for two day on how to conduct the 
interview, content of the questionnaire, data quality, and 
ways to approach respondents. The first author checked 
the questionnaires for completeness every day. Incom-
plete questionnaires were excluded. Five percent of the 
interviewed participants were randomly selected and re-
interviewed by the first author.
Laboratory method
Cord blood was screened for CMV-specific IgM using 
the ELISA test kits (Diagnostic Automation, Inc., USA) 
according to manufacturer’s guideline. Briefly, purified 
CMV antigen is coated on the surface of micro wells. 
Participant’s serum was then added to wells. If antibody 
is there in the serum, then it would bind to the antigen 
that is coated on the well. All unbound materials are 
washed away and an enzyme conjugate is added to the 
well. The conjugate, then binds to the antibody-antigen 
complex. Excess enzyme conjugate is washed off and 
TMB Chromogenic Substrate is added. Intensity of the 
color generated by the bound conjugate is proportional 
to the amount of IgM specific antibody present in the 
sample. Results are then read by a micro-well reader 
compared in a parallel manner with calibrator and con-
trols. Quantitative analysis for CMV and Rubella spe-
cific IgM (Siemens, Germany) were performed, and the 
assay result interpreted as IU/mL. The manufacturer’s 
instructions were followed for the cutoff points, which 
was  <1.1  IU/mL for CMV IgG and IgM. Results  <1.0 
OD value was considered negative for Rubella IgM. 
Whereas, maternal venous blood was analyzed by using 
Elecsys (cobas e 411) Roche reagent screened for CMV 
specific for IgG and IgM.
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Data analysis
The data were entered (with double entry) and cleaned 
with Epidata version 3.1, and analyzed using SPSS ver-
sion 20. Statistical significance was considered when P 
value  <0.05. newborn CMV specific IgM and maternal 
CMV-IgG & IgM prevalence was determined by dividing 
the number of infected individuals by the total number 
of individuals screened for CMV infection. Frequency 
distribution tables were used to quantify participant’s 
age range, gestation, occupation, parity and risk factors 
of CMV positivity rate. Newborns that had positive result 
for CMV specific IgM infection were low in number and 
therefore, a regression was not computed.
However, logistic regression analysis was used to quan-
tify the effect of different clinical and obstetrical related 
risk factors on maternal CMV seroprevalence. 95 % confi-
dence intervals were calculated for odds ratio. Values were 
considered statistically significant when P-value <0.05.
Results
Socio demographic characteristics
A total of 312 study participants (156 infants and 156 
mothers) were enrolled. Eighty-one male and 75 female 
newborns with a mean and standard deviation of weight 
in gram, height, and circumference in cm, 3.0  ±  0.6, 
41.9 ±  6.87, and 32.7 ±  3.1 respectively. The mean age 
of the mothers was 26.2 ± 5.0, with age range of 18-45. 
Of 156 study participants, 48.7  % were under 25. The 
majority of the participants (46.2 %) had at least second-
ary education. The majority were married (99.4  %) and 
82.7 % were housewives (Table 1).
Congenital and maternal cytomegalovirus infection
Overall, zero rubella and 2/156 [1.3 %; 95 % CI: 0.0–3.8] 
recent cytomegalovirus (CMV-IgM) infection was found 
among newborns. Out of the total 156 mothers 149 
[95.5 %; 95 % CI: 92.3–98.7) had positive result for anti-
CMV-IgG antibodies and 8 (5.5 %; 95 % CI: 1.3–9.0) were 
positive for CMV-IgM. Seven (4.5  %) mothers negative 
for CMV. These were categorized into four types of re-
sponses. The first category was CMV-IgM positive new-
borns, most likely primary infection. The second category 
had previous exposure to CMV [IgG (+) plus IgM (−)]. 
This constituted 90.4  % of the women. The third group 
was those with active (primary/latent) infection [IgG (+) 
plus IgM (+)] and this consisted of 5.1  % mothers. The 
last category of women was those who had sero-negative 
[IgG (−) plus IgM (−)] test result (Table 2).
Risk factors
For analysis between risk factors and congenital cyto-
megalovirus infection, regression was not done due to 
less number of positive newborns.
Whereas, cytomegalovirus recent infection was signifi-
cantly isolated from mothers with history of transfusion 
(25.0 %, OR 0.09, 95 % CI 0.0–0.3, P = 0.006) than have 
not been transfused. Mothers who had no transfusion his-
tory were 91 % odds less likely to acquire cytomegalovirus 
infection. History of abortion was also one of an inde-
pendent risk factor (OR 0.02, 95 % CI 0.0–0.6, P = 0.023), 
in which, mothers with history of abortion were 98 % odds 
less likely to acquire cytomegalovirus infection. HIV posi-
tive mothers were 5.0 times having odds of Cytomegalo-
virus infection than sero-negative mothers (OR 5.0, 95 % 
CI 1.5–15.8, P  =  0.034). Furthermore, Cytomegalovirus 
infection was significantly more prevalent in mothers who 
are in multi parity stage than null parity (OR 0.08, 95 % CI 
0.01–0.7, P = 0.022) (Table 3).
Cytomegalovirus infection among the mothers: 48.7 % 
were between age groups of ≤25, 46.8  % were between 
26-30, and 4.5 % were above 32.The infection prevalence 
among age groups ≤30, and ≥31 were 85.2  % (OR 2.3, 
95  % CI 0.03–2.3), and 14.8  % respectively. However, 
based on the logistic regression analysis no statically sig-
nificant variables were found. There was no significant 
association detected between CMV sero-prevalence and 
maternal educational, and occupation status (Table 4).
Discussion
The seroprevalence of CMV varies according to stud-
ies conducted in different parts of the world. But, it has 
been reported that 0.2 to 2 % of live birth have congenital 
CMV infection, considering CMV as the leading cause 
of congenital infections worldwide [13–15]. The fetus is 
at risk of acquiring CMV infection either through intra-
uterine or during delivery. Intrauterine transmission 
of CMV infection may occur following either primary 
or recurrent infection [16, 17]. Involvement of central 
nervous system (CNS), including late central nervous 
system sequelae, primarily sensory neuronal deafness is 
the most important clinical manifestation in 10–20 % of 
such CMV congenital infected infants [18]. Screening of 
mothers for CMV and early diagnosis play an important 
role to minimize CMV congenital infection and its seri-
ous consequences. However, to our knowledge this is the 
first data in Ethiopia concerning epidemiology of congen-
ital CMV and rubella among newborns.
The present study showed that Cytomegalovirus spe-
cific IgM was detected in 1.3  % of the newborns in 
their umbilical cord. CMV-IgG antibodies evaluation in 
umbilical cord blood was not performed because of the 
absence of a discriminative test to identify congenitally 
infected newborns. This might be due to the high preva-
lence of CMV seropositivity in developing countries [19–
21], and the possibility of IgG antibodies transmission 
from mothers to fetuses [22].
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Our finding was comparable with other studies; 1.1 % 
in Brazil [23], 2 % in Havana, Cuba [24], 2 % in Iran [25]. 
However, it was in contrast to other findings; 0.1  % in 
Turkey [26], 0.9 % in Thailand [27], 0.9 % in Korea [28], 
17.8 % in Egypt [29], 21.6 % in India [30], 18.7 % in Delhi 
[31], 4.8 % in Finland [32]. A higher frequency of CMV 
IgM detection (30 %) is normally found in newborns of 
mothers with poor obstetrical history or abnormali-
ties during pregnancy [33]. Our findings differ from this 
observation, because the study participants were among 
healthy/asymptomatic newborns.
The relationship between maternal and fetal/neonatal 
infection has been mentioned that pregnant patients with 
active CMV infection were at risk of having congenitally 
infected children when compared with those in whom 
viral activity was not detected during pregnancy [24].
As the IgM does not cross the placental barrier, the 
IgM obtained in cord serum samples could originated 
from an active CMV infection occurring in babies dur-
ing pregnancy or delivery. It is generally understood 
that pregnant women infected with CMV can transmit 
this infection during pregnancy, and risk is higher for 
a mother with primary infection (5–15  %) than for one 
with non-primary infection (<2  %) [34]. However this 
Table 1 Distributions of Cytomegalovirus infection along with maternal (n = 312) demographic characteristics, St.Paul’s 
Hospital Millennium Medical College, Addis Ababa, 2015
Characteristics Seroprevalence Total n (%)
Positive n (%) Negative n (%)
Sex newborn Male NA NA 81 (51.9)
Female NA NA 75 (48.1)
Income ethiopian birr +1500 81 (51.9)
1500–2500 55 (35.3)
>2500 20 (12.8)
Maternal age +25 73 (49.0) 3 (42.9) 76 (48.7)
26–35 69 (46.3) 4 (57.1) 73 (46.8)
36+ 7 (4.7) 0 7 (4.5)
Marital status Married 148 (99.3) 7 (100.0) 155 (99.4)
Others 1 (0.7) 0 1 (0.6)
Educational Illiterate 32 (21.5) 2 (28.6) 34 (21.8)
Primary 41 (27.5) 0 41 (26.3)
Secondary 67 (45.0) 5 (71.4) 72 (46.2)
Higher education 9 (6.0) 0 9 (5.8)
Occupation Housewife 123 (82.6) 6 (85.7) 129 (82.7)
Other 26 (17.4) 1 (14.3) 27 (17.3)
Blood transfusion history Yes 10 (6.7) 0 10 (6.4)
No 139 (93.3) 7 (100.0) 146 (93.6)
HIV Positive 2 (1.3) 0 2 (1.3)
Negative 147 (98.7) 7 (100.0) 154 (98.7)
Under five children in the household None 87 (58.4 %) 3(42.9) 90 (57.7)
1–2 59 (39.6) 3 (42.9) 62 (39.7)
3+ 3 (2.0) 1 (14.3) 4 (2.6)
History of abortion Yes 43 (28.9) 2 (28.6) 46 (29.5)
No 106 (71.1) 5 (71.4) 110 (70.5)
Parity +1 62 (41.6) 2 (28.6) 64 (41.0)
2–4 80 (53.7) 5 (71.4) 85 (54.5)
5+ 7 (4.7) 0 7 (4.5)
Table 2 Seroprevalence of CMV-specific IgG and IgM anti-
bodies among newborn and their mother (n = 312) in St.
Paul’s Hospital millennium Medical College, Addis Ababa, 
2015
Immune response Number % Interpretation
IgM(+) newborn 2 (1.3) Recent infection
IgG(+) IgM(−) mother 141 (90.4) Previous exposure
IgG(+) IgM(+) mother 8 (5.1) Active (primary/latent) infection
IgG(−) IgM(−) mother 7 (4.5) Susceptible for primary infection
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relationship could not be assessed in our study, since we 
could not differentiate women by type of infection.
Although, IgM assay is still considered as a reason-
able tool for congenital CMV infection diagnosis [35], it 
was reported that only 45–80  % of babies congenitally 
infected with CMV could be recognized by detection 
of IgM [36]. Thus, looking at polymerase chain reaction 
usage for accurate and effective diagnosis of this patho-
gen is unquestionable.
In many developing countries, the burden of CRS 
is under-estimated [37]. Also Ethiopia lacks informa-
tion regarding the burden of CRS, thus intensive types 
of research is important for the decision to introduce 
rubella-containing vaccine in the national immuniza-
tion program. In this study, Rubella specific IgM was 
not detected from cord blood samples. This is in con-
trast with another study where it was present in 2  % of 
cases in Sudan [38]. This might be because our research 
Table 3 Association of  maternal CMV—IgM with  Obstetrical, socio-demographical and  clinical characteristic of  the 
mother (n = 156) in SPHMMC, Addis Ababa, Ethiopia 2015
COR Crude Odds Ratio, AOR Adjusted Odds Ratio, CI Confidence Interval
Characteristics CMV-IgM status COR (95 % CI) P value AOR (95 % CI) P value
Positive n (%) Negative n (%)
Age
 +25 2 (25.0) 74 (50.0) 14.8 (1.7–128) 0.014 1.8 (0.1–32.0) 0.81
 26–35 4 (50.0) 69 (46.6) 6.9 (1.01–47.0) 0.049 1.7 (0.13–23.9) 0.83
 36+ 2 (25.0) 5 (3.4) 1 1
Income
 +1500 2 (25.0) 79 (53.4) 2.1 (0.2–24.1) 0.56 1.36 (0.1–18.1) 0.82
 1500–2500 5 (62.5) 50 (33.8) 0.5 (0.1–4.8) 0.57 0.5 (0.05–5.2) 0.57
 >2500 1 (12.5) 19 (12.8) 1 1
Educational status
 Illiterate 3 (37.5) 31 (20.9) 2.9 (0.4–21) 0.30 0.8 (0.034–21.2) 0.90
 Primary 1 (12.5) 40 (27.0) 11.4 (0.9–143) 0.06 8.7 (0.3–247.5) 0.20
 Secondary 3 (37.5) 69 (46.6) 10 (1.2-82.3) 0.03 15.7 (0.5–485.0) 0.12
 Higher education 1 (12.5) 8 (5.4) 1 1
Occupation
 Housewife 6 (75.0) 123 (83.1) 1 1
 Other 2 (25.0) 25 (16.9) 0.6 (0.12–3.2) 0.60 0.6 (0.12–3.2) 0.60
Blood transfusion history
 Yes 2 (25.0) 8 (5.4) 5.8 (1.02–33.6) 0.048 0.09 (0.0–0.3) 0.006
 No 6 (75.0) 140 (94.6) 1 1
HIV-sero status
 Positive 1 (12.5) 1 (0.7) 0.048 (0.003–0.8) 0.038 5.0 (1.5–15.8) 0.034
 Negative 7 (87.5) 147 (99.3) 1 1
Under five children in the household
 None 4 (50.0 %) 86 (58.1) 1
 1–2 3 (37.5) 59 (39.9) 0.92 (0.2–4.2) 0.91
 3+ 1 (12.5) 3 (2.0) 0.14 (0.01–1.6) 0.12
History of abortion
 Yes 6 (75.0) 39 (26.4) 0.12 (0.02–0.6) 0.012 0.02 (0.0–0.6) 0.023
 No 2 (25.0) 109 (73.6) 1 1
Pregnancy frequency
 +1 1 (12.5) 63 (42.6) 1 1
 2–4 5 (62.5) 80 (54.0) 0.6 (0.12–3.7) 0.63 0.6 (0.12–3.7) 0.63
 5+ 2 (25.0) 5 (3.4) 0.08 (0.01–0.7) 0.022 0.08 (0.01–0.7) 0.022
Hearing loss
 Yes 1 (12.5) 1 (0.7) 0.05 (0.003–0.8) 0.038 0.01 (0.0–1.9) 0.08
 No 7 (87.5) 147 (99.3) 1 1
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was conducted among healthy/asymptomatic newborns, 
whereas the other study was on symptomatic children.
In this study the maternal prevalence of anti-CMV 
IgG was 95.5 %, which is comparable with other research 
findings in a similar setting [39] and different studies 
in developing countries such as; 77.3  % in Kenya [19], 
97.5 % in Sudan [40], 96 % in Egypt [21], 92 % in Nigeria 
[41], and 87 % in Gambia [42].
Cytomegalovirus specific IgM has been detected from 
eight (5.1  %) mothers. This is in agreement with stud-
ies in other region; 4  % in Nigeria [41], 8.1  % in Kenya 
[19], 6 % in Sudan [40]. However, our finding is in con-
trast with other studies in similar setting [39] and 2.5 % 
in Iran [43], 1.7 % in Korea [44]. This might be because of 
high numbers of immune compromised participants and 
toddlers, socio-economic and geographical distribution 
difference. HIV-infected women are often CMV sero-
positive and experience more frequent CMV recurrences 
with progressive immune impairment [45]. The risk for 
infant mortality is increased in HIV-CMV-coinfected 
infants, and there is accelerated progression of CNS dis-
ease in survivors, especially developmental delay and 
worsening motor deficits [7, 46].
Multiple risk factors were identified between CMV—
IgM positivity rate and maternal characteristics. Cyto-
megalovirus—IgM was significantly detected from 
mothers with history of transfusion, history of abortion, 
multi parity and HIV sero-positive. Similarly, those risk 
factors were observed in different studies [19, 40, 45]. In 
the current study age and socio-economic status were not 
Table 4 Association of  Anti-CMV antibodies with  Obstetrical, socio-demographical and  clinical characteristic of  the 
mother (n = 156) in SPHMMC, Addis Ababa, Ethiopia 2015
COR Crude Odds Ratio, AOR Adjusted Odds Ratio, CI Confidence Interval
Characteristics CMV-IgG status COR (95 %CI) P value AOR (95 % CI) P value
Positive n (%) Negative n (%)
Age
 +30 127 (85.2) 5 (71.4) 2.3 (0.42–12.6) 0.33 0.3 (0.03–2.3) 0.22
 31+ 22 (14.8) 2 (28.6) 1
Income
 +1500 79 (53.0) 2 (28.6) 0.5 (0.04–5.6) 0.56 0.6 (0.1–7.5) 0.68
 1500–2500 51 (34.2) 4 (57.1) 1.5 (0.16–14.2) 0.73 1.6 (0.16-16.5) 0.68
 >2500 19 (12.8) 1 (14.3) 1 1
Educational status
 Less than 8th grade 73 (49.0) 2 (28.6) 0.42(0.1–2.2) 0.30 0.4 (0.1–2.0) 0.25
 More than 9th grade 76 (51.0) 5 (71.4)
Occupation
 Housewife 123 (82.6) 6 (85.7) 1.3 (0.15–10.9) 0.83 1.8 (0.2–16.7) 0.61
 Other 26 (17.4) 1 (14.3) 1
Blood transfusion history
 Yes 10 (6.7) 0 NA
 No 139 (93.3) 7 (100.0)
HIV
 Positive 2 (1.3) 0 NA
 Negative 147 (98.7) 7 (100.0)
Under five children in the household
 None 87 (58.4 %) 3(42.9) 1
 1–2 59 (39.6) 3 (42.9) 1.5 (0.28–7.5) 0.64
 3+ 3 (2.0) 1 (14.3) 9.7 (0.76–122.4) 0.08
History of abortion
 Yes 43 (28.9) 2 (28.6) 0.9 (0.2–5.3) 0.99 0.8 (0.12–4.8) 0.78
 No 106 (71.1) 5 (71.4) 1 1
Pregnancy frequency
 +2 104 (41.6) 5 (71.4) 1 1
 3+ 45 (53.7) 2 (28.6) 1.1 (0.2–5.8) 0.93 2.2 (0.24–20.3) 0.47
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significantly associated with CMV sero-positivity, while 
different studies suggest individuals with low income and 
elderly women were at higher risk of CMV-infection [47].
The limitations of our study include (i) the lack of long-
term follow up data for infected infants; (ii) study design 
precluded inclusion of molecular technique and neo-
natal urine culture as a gold standard method; and (iii) 
the timing of maternal CMV seroconversion couldn’t be 
assessed by early pregnancy serology.
Conclusion
In general, although this study showed low congenital 
Cytomegalovirus infection among newborns, there is 
high seroprevalence of CMV infection among mothers 
at our center; and is likely to be a reflection of the over-
all high prevalence among adult Ethiopians. These data 
might therefore; help to create awareness for clinicians in 
Ethiopia, and CMV associated complications should be 
taken into consideration during management of congeni-
tal related viral diseases. Future studies, including large 
scale surveillance throughout Ethiopia might be needed 
before national screening and universal prevention meas-
ures should be considered.
Although Rubella was not detected in this study, there 
is high number of individuals with congenital Rubella 
syndrome (CRS). Therefore, a large scale study should 
be conducted to recommend introduction of national 
Rubella immunization.
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